Free Press Journal
  • New HIV drug effectively reduces virus, boosts immunity: Study

    New York: A new intravenous HIV drug has shown to be effective in reducing virus, boost immunity among patients with advanced, multi-drug resistant HIV infection, results of a phase-III trial has showed. As the first monoclonal antibody approved by the US Food and Drug Administration (FDA) in March 2018 to treat HIV, ibalizumab is a promising option for individuals who have tried several other drug therapies. Ibalizumab targets the primary receptor for HIV